GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical company’s blood cancer pipeline.
The experimental therapy is being developed for multiple myeloma and is expected to enter Phase I clinical trials in 2027.
Under the agreement, GSK will make an upfront payment for full global rights to the program. Privately held Chimagen will also be eligible for development and commercial milestone payments that could bring the transaction’s total value to $750 million.
The therapy uses a trispecific approach that binds to T cells while simultaneously targeting two validated tumor-associated antigens.
T-cell engagers are designed to redirect a patient’s immune cells toward cancer cells. Existing therapies in the category have demonstrated significant efficacy in multiple myeloma, but tolerability can be a limiting factor.
Chimagen’s candidate is designed to potentially produce deeper and more durable responses while improving tolerability compared with existing TCEs.
If successful, GSK believes the profile could make the therapy appropriate for broader use and potentially earlier treatment of multiple myeloma.
The commercial opportunity is substantial. GSK cited forecasts estimating that the U.S. T-cell engager market for multiple myeloma could exceed $10 billion by 2032.
Multiple myeloma is the world’s third most common blood cancer, with approximately 180,000 new cases diagnosed globally each year. Although treatments can control the disease, multiple myeloma is generally not considered curable and can eventually become resistant to existing therapies.
The acquisition also deepens an existing relationship between GSK and Chimagen.
GSK previously reached an agreement to acquire CMG1A46, Chimagen’s clinical-stage dual CD19 and CD20-targeted T-cell engager. That candidate is currently in Phase I development for B-cell malignancies and B-cell dependent autoimmune disorders.
For GSK, the new agreement fits a broader oncology strategy centered on acquiring differentiated assets that act against clinically validated targets.
The company currently has a major focus on blood cancers and women’s cancers while expanding into areas including lung and gastrointestinal cancers.
Chimagen is a clinical-stage biotechnology company developing multi-specific T-cell and natural killer cell engagers through proprietary antibody engineering platforms.
KEY QUOTES:
“Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease.”
Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK
“Our mission has always been to translate cutting-edge innovation into life-changing medicines. Working with GSK combines our precision T-cell engager programme with their global development and commercial capabilities to redefine care for multiple myeloma patients. This agreement also marks another major milestone for our platforms as we continue to build an industry-leading pipeline of multi-specific antibody candidates.”
Zhenhao Zhou, CEO of Chimagen Biosciences
